论文部分内容阅读
目的观察环孢素A(CsA)治疗系统性红斑狼疮(SLE)相关难治性血小板减少的长期疗效及安全性。方法对我科收治的16例SLE相关难治性血小板减少患者使用CsA治疗,并长期随访观察CsA的疗效及不良反应。结果显效8例,有效6例,总有效率为87.5%。有效的14例患者随访(38±2.5)个月,治疗3月平均血小板值(137.9±64.1)×109/L,随访过程中各患者最低血小板值(85.4±39.5)×10~9/L,与用CsA治疗前相比差异均有统计学意义(P<0.001),且未见严重不良反应。结论小剂量CsA是治疗SLE相关难治性血小板减少的一种安全、有效的方法,不良反应轻微。
Objective To observe the long-term efficacy and safety of cyclosporin A (CsA) in the treatment of systemic lupus erythematosus (SLE) -related refractory thrombocytopenia. Methods 16 cases of SLE-related refractory thrombocytopenia admitted to our department were treated with CsA. The efficacy and adverse reactions of CsA were observed after long-term follow-up. Results in 8 cases markedly effective in 6 cases, the total effective rate was 87.5%. Fourteen patients were followed up for an average of (38 ± 2.5) months. The average platelet count (137.9 ± 64.1) × 109 / L at March was 85.4 ± 39.5 × 10-9 / L during follow-up, Compared with CsA before treatment, the differences were statistically significant (P <0.001), and no serious adverse reactions. Conclusion Low-dose CsA is a safe and effective method for the treatment of SLE-related refractory thrombocytopenia with mild adverse reactions.